dual agonist glp 1 glucagon The Effects of GLP-1/GIP Receptor Agonism on Secretion—A Review Discovery of Biased Dual-Agonists of

The exenatide group in this study, however, showed a significant increase in the mean cardiac output by 1.2 L/min, a reduced total peripheral resistance by the mean of 120 dyns/cm 5 , and a significantly reduced urinary sodium: creatinine ratio without a significant change in the BP [39]

DPP4 deficiency in rats A major part of the literature is dealing rather with DPP4-KO in rats than in mice

Following strict inclusion and exclusion criteria, 55 articles were included in the analysis

Obesity Drug Market Overview and Growth Potential The US obesity drug market is on a meteoric rise, projected to soar past USD 73 billion by 2034

S., Nakagawa S., Malberg J

Available from: Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D et al (2024) Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial